Title:
COMBINED USE OF UBENIMEX AND IMMUNE CHECKPOINT INHIBITORS
Document Type and Number:
WIPO Patent Application WO/2022/250070
Kind Code:
A1
Abstract:
The purpose of the present invention is to provide a more effective treatment method for cancer treatment that utilizes the tumor immune system. A further purpose of the present invention is to provide, as a more effective tumor immunotherapy, a drug that enhances antitumor, pro-inflammatory and anti-inflammatory cytokine production. A further purpose of the present invention is to provide, as a more effective tumor immunotherapy, a drug that increases tumor-infiltrating lymphocytes. This anti-tumor agent has ubenimex as the active component, and is dosed in combination with anti-PD-1 antibodies, an anti-PD-L1 antibodies and/or an anti-CTLA-4 antibodies, which are immune checkpoint inhibitors (ICIs). This ubenimex and ICI combination therapy brings about improvement of the tumor immune system when compared with the use of either of these alone, and brings about many benefits in the treatment of malignant tumors.
More Like This:
Inventors:
IGO NAOKO (JP)
NAGAI DAICHI (JP)
SEKINE KEIKO (JP)
AIJIMA MICHIKO (JP)
NAGAI DAICHI (JP)
SEKINE KEIKO (JP)
AIJIMA MICHIKO (JP)
Application Number:
PCT/JP2022/021320
Publication Date:
December 01, 2022
Filing Date:
May 25, 2022
Export Citation:
Assignee:
NIPPON KAYAKU KK (JP)
International Classes:
A61K38/05; A61K39/395; A61P35/00; A61P43/00
Domestic Patent References:
| WO2019175113A1 | 2019-09-19 |
Foreign References:
| JP2019506438A | 2019-03-07 | |||
| JP2012158605A | 2012-08-23 | |||
| JP2019506438A | 2019-03-07 | |||
| JP2020515600A | 2020-05-28 | |||
| JP2021506781A | 2021-02-22 |
Other References:
KEIKO SEKINE: "3782: Investigation of the apoptosis-inducing ability of various aminopeptidase inhibitors including bestatin in tumor cell lines", JAPANESE JOURNAL OF CANCER RESEARCH, vol. 91, no. Suppl., 1 January 2000 (2000-01-01), JP , pages 582, XP009541402, ISSN: 0910-5050
GARANCHER ALEXANDRA; SUZUKI HIROMICHI; HARICHARAN SVASTI; CHAU LIANNE Q.; MASIHI MEHER BEIGI; RUSERT JESSICA M.; NORRIS PAULA S.; : "RETRACTED ARTICLE: Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma", NATURE NEUROSCIENCE, vol. 23, no. 7, 18 May 2020 (2020-05-18), New York, pages 842 - 853, XP037641971, ISSN: 1097-6256, DOI: 10.1038/s41593-020-0628-4
"Pharmaceutical Interview Form", October 2020, NIPPON KAYAKU CO., LTD., article "Antineoplastic Drugs: Bestatin Capsules 10 mg and Bestatin Capsules 30 mg"
GARANCHER ALEXANDRA; SUZUKI HIROMICHI; HARICHARAN SVASTI; CHAU LIANNE Q.; MASIHI MEHER BEIGI; RUSERT JESSICA M.; NORRIS PAULA S.; : "RETRACTED ARTICLE: Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma", NATURE NEUROSCIENCE, vol. 23, no. 7, 18 May 2020 (2020-05-18), New York, pages 842 - 853, XP037641971, ISSN: 1097-6256, DOI: 10.1038/s41593-020-0628-4
"Pharmaceutical Interview Form", October 2020, NIPPON KAYAKU CO., LTD., article "Antineoplastic Drugs: Bestatin Capsules 10 mg and Bestatin Capsules 30 mg"
Attorney, Agent or Firm:
EINSEL Felix-Reinhard et al. (JP)
Download PDF: